AU2019240413A1 - Treatment and prophylaxis of amyloidosis - Google Patents

Treatment and prophylaxis of amyloidosis Download PDF

Info

Publication number
AU2019240413A1
AU2019240413A1 AU2019240413A AU2019240413A AU2019240413A1 AU 2019240413 A1 AU2019240413 A1 AU 2019240413A1 AU 2019240413 A AU2019240413 A AU 2019240413A AU 2019240413 A AU2019240413 A AU 2019240413A AU 2019240413 A1 AU2019240413 A1 AU 2019240413A1
Authority
AU
Australia
Prior art keywords
antibody
seq
concentration
set forth
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019240413A
Other languages
English (en)
Inventor
Robin Barbour
Philip J. DOLAN III
Tarlochan Nijjar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of AU2019240413A1 publication Critical patent/AU2019240413A1/en
Priority to AU2023202109A priority Critical patent/AU2023202109A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019240413A 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis Abandoned AU2019240413A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202109A AU2023202109A1 (en) 2018-03-23 2023-04-05 Treatment and prophylaxis of amyloidosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647341P 2018-03-23 2018-03-23
US62/647,341 2018-03-23
PCT/US2019/023528 WO2019183448A1 (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202109A Division AU2023202109A1 (en) 2018-03-23 2023-04-05 Treatment and prophylaxis of amyloidosis

Publications (1)

Publication Number Publication Date
AU2019240413A1 true AU2019240413A1 (en) 2020-10-08

Family

ID=66041747

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019240413A Abandoned AU2019240413A1 (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis
AU2023202109A Pending AU2023202109A1 (en) 2018-03-23 2023-04-05 Treatment and prophylaxis of amyloidosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202109A Pending AU2023202109A1 (en) 2018-03-23 2023-04-05 Treatment and prophylaxis of amyloidosis

Country Status (13)

Country Link
US (1) US20210017278A1 (https=)
EP (1) EP3768311A1 (https=)
JP (1) JP7217287B2 (https=)
KR (1) KR20200143400A (https=)
CN (1) CN112040983A (https=)
AU (2) AU2019240413A1 (https=)
BR (1) BR112020019172A2 (https=)
CA (1) CA3095100A1 (https=)
EA (1) EA202092264A1 (https=)
MX (1) MX2020009920A (https=)
MY (1) MY203432A (https=)
SG (1) SG11202009295YA (https=)
WO (1) WO2019183448A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2237803T3 (en) * 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
SG10201604104PA (en) * 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis

Also Published As

Publication number Publication date
EP3768311A1 (en) 2021-01-27
MY203432A (en) 2024-06-27
CN112040983A (zh) 2020-12-04
CA3095100A1 (en) 2019-09-26
BR112020019172A2 (pt) 2021-01-26
KR20200143400A (ko) 2020-12-23
AU2023202109A1 (en) 2023-05-18
EA202092264A1 (ru) 2020-12-03
JP7217287B2 (ja) 2023-02-02
WO2019183448A1 (en) 2019-09-26
MX2020009920A (es) 2020-12-10
US20210017278A1 (en) 2021-01-21
JP2021518393A (ja) 2021-08-02
SG11202009295YA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
US20210077407A1 (en) Antibody Formulations and Methods
AU2016250388B2 (en) Treatment for rheumatoid arthritis
US20210079078A1 (en) Compositions for Treating Amyloidosis
KR20160044030A (ko) 종양 치료용 항-ｂ7-ｈ1 항체
JP2020536097A5 (https=)
JP7419262B2 (ja) 抗ｐｃｓｋ９抗体を含む製剤およびその使用
IL300376A (en) Inflammatory cytokines and fatigue in subjects with complement-mediated disease
AU2020231081A1 (en) Methods of treating AL amyloidosis
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
JP2018533588A (ja) 治療パラダイム
KR20230142834A (ko) 항-cd38 항체 및 이의 용도
US20210017278A1 (en) Treatment and Prophylaxis of Amyloidosis
CN114728060A (zh) 使用白介素-17（il-17）拮抗剂治疗狼疮性肾炎的方法
EA044759B1 (ru) Лечение и профилактика амилоидоза
WO2016102530A1 (en) Cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome
HK40008815B (en) Compositions for treating amyloidosis
WO2025170969A1 (en) Methods of treating al amyloidosis
WO2023230605A1 (en) A method of treating solid tumor
CN120019073A (zh) 一种治疗实体瘤的方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted